.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Johnson and Johnson
Cantor Fitzgerald
Fuji
Novartis
Chubb
Fish and Richardson
Express Scripts
QuintilesIMS
Baxter

Generated: July 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Abuse-resistant amphetamine prodrugs
Abstract:The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Inventor(s): Mickle; Travis (Coralville, IA), Krishnan; Suma (Belvedere, CA), Bishop; Barney (Annandale, VA), Lauderback; Christopher (Blacksburg, VA), Moncrief; James Scott (Christiansburg, VA), Oberlender; Robert (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA), Paul; Bernhard J. (Lexington, MA), Verbicky; Christopher A. (Broadalbin, NY)
Assignee: Shire LLC (Florence, KY)
Application Number:12/201,794
Patent Claims: 1. A pharmaceutical composition comprising (a) L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof and (b) a pharmaceutically acceptable additive.

2. A pharmaceutical composition as defined in claim 1, wherein said pharmaceutical composition is suitable for oral dosing.

3. A pharmaceutical composition as defined in claim 2, comprising from 2.5 mg to 500 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition as defined in claim 3, comprising from 10 mg to 250 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition as defined in claim 4, comprising from 25 mg to 75 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition as defined in claim 5, comprising 30 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition as defined in claim 5, comprising 50 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition as defined in claim 5, comprising 70 mg of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition as defined in claim 2, comprising a salt of L-lysine-d-amphetamine.

10. A pharmaceutical composition as defined in claim 9, wherein said salt is a mesylate salt.

11. A pharmaceutical composition as defined in claim 10, wherein said salt is a dimesylate salt.

12. A pharmaceutical composition comprising L-lysine-d-amphetamine dimesylate and a pharmaceutically acceptable additive, wherein said pharmaceutical composition has a water content of about 1% to about 10% by Karl Fischer analysis.

13. A pharmaceutical composition as defined in claim 12, wherein said pharmaceutical composition has a water content of about 1% to about 8% by Karl Fischer analysis.

14. A pharmaceutical composition as defined in claim 13, wherein said water content is about 2% to about 7% by Karl Fischer analysis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
US Army
Medtronic
Chubb
McKesson
Federal Trade Commission
Moodys
McKinsey
Fuji
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot